The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A randomized phase II (RP2) trial of ridaforolimus (R) compared with progestin (P) or chemotheraphy (C) in female adult patients with advanced endometrial carcinoma.
A. M. Oza
Research Funding - ARIAD
A. Poveda
No relevant relationships to disclose
A. R. Clamp
No relevant relationships to disclose
S. Pignata
Consultant or Advisory Role - Roche; Schering-Plough
Honoraria - Merck; Roche; Schering-Plough
G. Scambia
No relevant relationships to disclose
J. M. Del Campo
No relevant relationships to disclose
M. McCormack
No relevant relationships to disclose
L. Sevcik
No relevant relationships to disclose
B. M. Schwartz
No relevant relationships to disclose
S. Guan
Employment or Leadership Position - Merck
Stock Ownership - Merck
R. Lee
Employment or Leadership Position - Merck
Stock Ownership - Merck
J. D. Cheng
Employment or Leadership Position - Merck
Stock Ownership - Merck
F. G. Haluska
Employment or Leadership Position - ARIAD
Stock Ownership - ARIAD